Cobimetinib
Sign in to save this workspacePrimary targets: MEK1, MEK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.644
CATDS
0.048
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Cobimetinib. Strongest target: MEK1 at 73.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MEK1 | 73.5% | 26.4% |
| 2 | MEK2 | 59.8% | 40.2% |
| 3 | TNIK | 30.5% | 69.5% |
| 4 | MINK_MINK1 | 21.7% | 78.3% |
| 5 | ERN1_IRE1 | 21.3% | 78.7% |
| 6 | ALK2_ACVR1 | 21.3% | 78.7% |
| 7 | C_MET | 18.7% | 81.3% |
| 8 | MST3_STK24 | 18.3% | 81.7% |
| 9 | GRK6 | 18.1% | 81.9% |
| 10 | AURORA_B | 17.2% | 82.8% |
| 11 | STK32C_YANK3 | 16.5% | 83.5% |
| 12 | FLT3 | 16.0% | 84.0% |
| 13 | TRPM7_CHAK1 | 15.1% | 84.9% |
| 14 | ALK6_BMPR1B | 14.7% | 85.3% |
| 15 | CK1G2 | 13.9% | 86.1% |
| 16 | COT1_MAP3K8 | 13.4% | 86.6% |
| 17 | TLK1 | 12.6% | 87.4% |
| 18 | CK2A2 | 12.5% | 87.5% |
| 19 | MLK4 | 12.0% | 88.0% |
| 20 | ERK1 | 12.0% | 88.0% |
Selectivity landscape
Where Cobimetinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Cobimetinib.
Annotations
Sign in to read and post annotations.
Loading…